James Abbruzzese, MD

Professor of Medicine
D. C. I. Distinguished Professor of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., The University of Chicago, 1978

Publications

Dong, Xiaoqun, Yanan Li, Hongwei Tang, Ping Chang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer.” Cancer Epidemiol 36, no. 2 (April 2012): 206–11. https://doi.org/10.1016/j.canep.2011.05.013.

PMID
21852217
Full Text

Chatterjee, Deyali, Matthew H. Katz, Asif Rashid, Hua Wang, Alina C. Iuga, Gauri R. Varadhachary, Robert A. Wolff, et al. “Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma.” Am J Surg Pathol 36, no. 3 (March 2012): 409–17. https://doi.org/10.1097/PAS.0b013e31824104c5.

PMID
22301497
Full Text

Dakik, Hassan K., Daniel J. Moskovic, Peter J. Carlson, Eric P. Tamm, Wei Qiao, Robert A. Wolff, James L. Abbruzzese, and David R. Fogelman. “The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.” Cancer Chemother Pharmacol 69, no. 2 (February 2012): 425–30. https://doi.org/10.1007/s00280-011-1705-x.

PMID
21850466
Full Text

Hammond-Thelin, Lisa A., Melanie B. Thomas, Michiko Iwasaki, James L. Abbruzzese, Yvonne Lassere, Christina A. Meyers, Paulo Hoff, et al. “Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies.” Invest New Drugs 30, no. 1 (February 2012): 316–26. https://doi.org/10.1007/s10637-010-9535-y.

PMID
20839029
Full Text

Estrella, Jeannelyn S., Asif Rashid, Jason B. Fleming, Matthew H. Katz, Jeffrey E. Lee, Robert A. Wolf, Gauri R. Varadhachary, et al. “Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation.” Cancer 118, no. 1 (January 1, 2012): 268–77. https://doi.org/10.1002/cncr.26243.

PMID
21735446
Full Text

Zhao, Qing, Asif Rashid, Yun Gong, Matthew H. Katz, Jeffrey E. Lee, Robert Wolf, Aparna Balachandran, et al. “Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis.” Ann Diagn Pathol 16, no. 1 (January 2012): 29–37. https://doi.org/10.1016/j.anndiagpath.2011.08.005.

PMID
22050964
Full Text

Katz, Matthew H. G., Huamin Wang, Aparna Balachandran, Priya Bhosale, Christopher H. Crane, Xuemei Wang, Peter W. T. Pisters, et al. “Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.” J Gastrointest Surg 16, no. 1 (January 2012): 68–78. https://doi.org/10.1007/s11605-011-1748-7.

PMID
22065318
Full Text

Kaseb, Ahmed O., E. Garrett-Mayer, J. S. Morris, L. Xiao, E. Lin, G. Onicescu, M. M. Hassan, et al. “Efficacy of bevacizumab plus erlotinib for advanced hepatocellular carcinoma and predictors of outcome: final results of a phase II trial.” Oncology 82, no. 2 (2012): 67–74. https://doi.org/10.1159/000335963.

PMID
22327795
Full Text

Fogelman, David, Mehrdad Jafari, Gauri R. Varadhachary, Henry Xiong, Susie Bullock, Harold Ozer, E. Lin, et al. “Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.” Cancer Chemother Pharmacol 68, no. 6 (December 2011): 1431–38. https://doi.org/10.1007/s00280-011-1601-4.

PMID
21479635
Full Text

Pages